A PHASE, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH LENVATINIB (E7080/MK-7902) VERSUS PEMBROLIZUMAB AND PLACEBO AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN CISPLATIN-INELIGIBLE PARTICIPANTS WHOSE TUMORS EXPRESS PD-L1, AND IN PARTICIPANTS INELIGIBLE FOR ANY PLATINUM-CONTAINING CHEMOTHERAPY REGARDLESS OF PD-L1 EXPRESSION (LEAP-011)
- Registry ID
- MK-7902-011
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2019-09-30
- Last update
- 2019-04-03
Conditions
Related clinical trials
- A PHASE III, OPEN-LABEL, RANDOMISED, MULTICENTRE, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN IN COMBINATION WITH RILVEGOSTOMIG IN PARTICIPANTS WITH HIGH-RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA (TROPION-UROTHELIAL04)
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN (MK-2870) CARCINOMA VERSUS INVESTIGATOR’S CHOICE OF NON-PLATINUM CHEMOTHERAPY IN PARTICIPANTS WITH PRETREATED LOCALLY ADVANCED/METASTATIC UROTHELIAL
- IZABRIGHT-BLADDER01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB
BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER
IN PARTICIPANTS WITH DISEASE PROGRESSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT
- A PHASE 1/2, SINGLE-ARM, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF NADOFARAGENE FIRADENOVEC INSTILLED TO THE RENAL PELVIS IN ADULT SUBJECTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC)
- MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRDBASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL
CANCER
- A RANDOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN
COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL
CANCER (DURAVELO-2)
View on source registry